Genvor（GNVR）株式概要ジェンボア・インコーポレイテッドは、農家が世界的な食糧安全保障を達成できるように設計された植物ベースの防衛技術を開発している。 詳細GNVR ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ 収益が 100 万ドル未満 ( $0 )過去5年間で収益は年間1.6%減少しました。 マイナスの株主資本 +1 さらなるリスクすべてのリスクチェックを見るGNVR Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.46該当なし内在価値ディスカウントEst. Revenue$PastFuture-7m12016201920222025202620282031Revenue US$1.0Earnings US$0.2AdvancedSet Fair ValueView all narrativesGenvor Incorporated 競合他社OSR HoldingsSymbol: NasdaqCM:OSRHMarket cap: US$16.6mMedicus PharmaSymbol: NasdaqCM:MDCXMarket cap: US$16.5mIN8bioSymbol: NasdaqCM:INABMarket cap: US$16.4mPassage BioSymbol: NasdaqCM:PASGMarket cap: US$16.8m価格と性能株価の高値、安値、推移の概要Genvor過去の株価現在の株価US$0.4652週高値US$3.0052週安値US$0.014ベータ578001.131ヶ月の変化-16.70%3ヶ月変化-42.73%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-88.55%最新ニュースお知らせ • May 23Genvor Incorporated Appoints Donald Kalkofen as Chief Financial OfficerGenvor Incorporated announced the appointment of Donald Kalkofen as Chief Financial Officer. In this role, Mr. Kalkofen will lead Genvor’s financial strategy as the company advances its dual-market commercialization plans across agriculture and human health and wellness. Mr. Kalkofen brings more than 20 years of Chief Financial Officer experience leading finance and operations across biotechnology, financial services, and technology, with a proven track record of guiding companies through initial public offerings and complex capital markets transactions. Most recently, he served as Chief Financial Officer of Alpha Cognition Inc., a publicly traded CNS-focused biotechnology company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s, where he led the preparations for the company’s successful NASDAQ listing and helped to establish new banking, audit committee, and investor relations functions. Prior to Alpha Cognition, Mr. Kalkofen served as Chief Financial Officer of Protagonist Therapeutics, a publicly traded clinical-stage biopharmaceutical company, where he helped guide the company’s strong growth and supported the company’s successful SOX 404(b) implementation. Earlier in his career, Mr. Kalkofen held Chief Financial Officer and senior finance leadership roles at Symantec Corporation and West Coast Bancorp, where he took the bank public on NASDAQ and led growth from $90 million to $1.5 billion in assets. Mr. Kalkofen is a Certified Public Accountant (inactive) and holds a Bachelor of Arts in Accounting from Washington State University.お知らせ • Feb 11Genvor, Inc. Announces the Publication of Peer-Reviewed Research Validated Its Proprietary Agm182 Antifungal Peptide Technology in PhytofrontiersGenvor Inc. announced the publication of peer-reviewed research validating its proprietary AGM182 antifungal peptide technology in PhytoFrontiers™?, a journal of the American Phytopathological Society. The study, conducted in collaboration with the United States Department of Agriculture's Agricultural Research Service (USDA-ARS), demonstrates that transgenic corn expressing AGM182 achieves significant pre-harvest resistance to Aspergillus flavus and aflatoxin contamination. Aflatoxins are naturally occurring toxic and carcinogenic compounds produced by Aspergillus flavus that contain corn and other crops, posing significant risks to human and animal health. Economic losses fromungal diseases in corn are substantial, with total annual U.S. losses estimated between $3 billion and $5 billion. Aflatoxin contamination alone has potential annual market impacts ranging from approximately $52 million in lower-risk years to $1.68 billion in high-risk years. The peer-reviewed publication follows Genvor's November 2025 announcement that the USPTO issued U.S. Patent No. 12,458,684 for transgenic corn with antifungal peptide AGM182, co-assigned with the USDA. Together, the patent and publication provide both intellectual property protection and independent scientific validation of the technology's commercial potential. The research was conducted at the USDA-ARS Food and Feed Safety Research Unit at the Southern Regional Research Center in New Orleans, Louisiana, in collaboration with scientists from Tuskegee University and Genvor. The study builds on Genvor's over 7-year Cooperative Research and Development Agreement (CRADA) with the USDA-ARS, which focuses on developing corn varieties resistant to pre-harvest aflatoxin contamination.お知らせ • Jan 28Genvor, Inc. Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, Effective February 2, 2026Genvor Inc. announced the appointment of Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, effective February 2, 2026. In this role, Dr. Stavrides will lead Genvor’s commercial strategy and execution, focusing on expanding strategic partnerships, licensing agreements, and collaboration opportunities with global agricultural companies. Dr. Stavrides brings more than 15 years of corporate experience in agrochemicals and biologicals, most recently serving as Global Product Management Lead, Biocontrols, at Syngenta. During his tenure, Dr. Stavrides and his team led the commercial evaluation of over 500 biological product concepts, managed over a dozen external collaborations, and oversaw over 50 product launches globally (microbials, extracts, pheromones), quadrupling revenues over a seven-year period. Previously, Dr. Stavrides held various global regulatory, strategy and marketing positions, in both agrochemicals and biocontrols. He has also served as company representative to the International Biocontrol Manufacturers Association (IBMA) for several years. Dr. Stavrides is a biochemist and also holds a Ph.D. in Genomics from Cambridge University (Human Genome Project) and an MBA from INSEAD.お知らせ • Dec 12Genvor Incorporated Auditor Raises 'Going Concern' DoubtGenvor Incorporated filed its 10-K on Dec 10, 2025 for the period ending Sep 30, 2025. In this report its auditor, Novogradac & Company LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Dec 06Genvor Incorporated announced that it expects to receive $7 million in fundingGenvor Incorporated announced that it will receive $70,00,000 in funding on December 5, 2025. The company will issue common shares and warrants in the transaction. The minimum investment accepted from any outside investor is $10,000. The company will issue securities pursuant to exemption provided under Regulation D.お知らせ • Aug 14Genvor Incorporated announced delayed 10-Q filingOn 08/13/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.最新情報をもっと見るRecent updatesお知らせ • May 23Genvor Incorporated Appoints Donald Kalkofen as Chief Financial OfficerGenvor Incorporated announced the appointment of Donald Kalkofen as Chief Financial Officer. In this role, Mr. Kalkofen will lead Genvor’s financial strategy as the company advances its dual-market commercialization plans across agriculture and human health and wellness. Mr. Kalkofen brings more than 20 years of Chief Financial Officer experience leading finance and operations across biotechnology, financial services, and technology, with a proven track record of guiding companies through initial public offerings and complex capital markets transactions. Most recently, he served as Chief Financial Officer of Alpha Cognition Inc., a publicly traded CNS-focused biotechnology company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s, where he led the preparations for the company’s successful NASDAQ listing and helped to establish new banking, audit committee, and investor relations functions. Prior to Alpha Cognition, Mr. Kalkofen served as Chief Financial Officer of Protagonist Therapeutics, a publicly traded clinical-stage biopharmaceutical company, where he helped guide the company’s strong growth and supported the company’s successful SOX 404(b) implementation. Earlier in his career, Mr. Kalkofen held Chief Financial Officer and senior finance leadership roles at Symantec Corporation and West Coast Bancorp, where he took the bank public on NASDAQ and led growth from $90 million to $1.5 billion in assets. Mr. Kalkofen is a Certified Public Accountant (inactive) and holds a Bachelor of Arts in Accounting from Washington State University.お知らせ • Feb 11Genvor, Inc. Announces the Publication of Peer-Reviewed Research Validated Its Proprietary Agm182 Antifungal Peptide Technology in PhytofrontiersGenvor Inc. announced the publication of peer-reviewed research validating its proprietary AGM182 antifungal peptide technology in PhytoFrontiers™?, a journal of the American Phytopathological Society. The study, conducted in collaboration with the United States Department of Agriculture's Agricultural Research Service (USDA-ARS), demonstrates that transgenic corn expressing AGM182 achieves significant pre-harvest resistance to Aspergillus flavus and aflatoxin contamination. Aflatoxins are naturally occurring toxic and carcinogenic compounds produced by Aspergillus flavus that contain corn and other crops, posing significant risks to human and animal health. Economic losses fromungal diseases in corn are substantial, with total annual U.S. losses estimated between $3 billion and $5 billion. Aflatoxin contamination alone has potential annual market impacts ranging from approximately $52 million in lower-risk years to $1.68 billion in high-risk years. The peer-reviewed publication follows Genvor's November 2025 announcement that the USPTO issued U.S. Patent No. 12,458,684 for transgenic corn with antifungal peptide AGM182, co-assigned with the USDA. Together, the patent and publication provide both intellectual property protection and independent scientific validation of the technology's commercial potential. The research was conducted at the USDA-ARS Food and Feed Safety Research Unit at the Southern Regional Research Center in New Orleans, Louisiana, in collaboration with scientists from Tuskegee University and Genvor. The study builds on Genvor's over 7-year Cooperative Research and Development Agreement (CRADA) with the USDA-ARS, which focuses on developing corn varieties resistant to pre-harvest aflatoxin contamination.お知らせ • Jan 28Genvor, Inc. Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, Effective February 2, 2026Genvor Inc. announced the appointment of Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, effective February 2, 2026. In this role, Dr. Stavrides will lead Genvor’s commercial strategy and execution, focusing on expanding strategic partnerships, licensing agreements, and collaboration opportunities with global agricultural companies. Dr. Stavrides brings more than 15 years of corporate experience in agrochemicals and biologicals, most recently serving as Global Product Management Lead, Biocontrols, at Syngenta. During his tenure, Dr. Stavrides and his team led the commercial evaluation of over 500 biological product concepts, managed over a dozen external collaborations, and oversaw over 50 product launches globally (microbials, extracts, pheromones), quadrupling revenues over a seven-year period. Previously, Dr. Stavrides held various global regulatory, strategy and marketing positions, in both agrochemicals and biocontrols. He has also served as company representative to the International Biocontrol Manufacturers Association (IBMA) for several years. Dr. Stavrides is a biochemist and also holds a Ph.D. in Genomics from Cambridge University (Human Genome Project) and an MBA from INSEAD.お知らせ • Dec 12Genvor Incorporated Auditor Raises 'Going Concern' DoubtGenvor Incorporated filed its 10-K on Dec 10, 2025 for the period ending Sep 30, 2025. In this report its auditor, Novogradac & Company LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Dec 06Genvor Incorporated announced that it expects to receive $7 million in fundingGenvor Incorporated announced that it will receive $70,00,000 in funding on December 5, 2025. The company will issue common shares and warrants in the transaction. The minimum investment accepted from any outside investor is $10,000. The company will issue securities pursuant to exemption provided under Regulation D.お知らせ • Aug 14Genvor Incorporated announced delayed 10-Q filingOn 08/13/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 13Genvor Incorporated announced delayed 10-Q filingOn 05/12/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 19Genvor Incorporated announced delayed 10-Q filingOn 02/18/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 01Genvor Incorporated announced delayed annual 10-K filingOn 01/31/2025, Genvor Incorporated announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Oct 23Genvor Incorporated Announces the Resignation of Judith S. Miller as Member of the Board of DirectorsOn August 7, 2024, Judith S. Miller resigned as a member of the Board of Directors of Genvor Incorporated (the Company).お知らせ • Aug 16Genvor Incorporated announced delayed 10-Q filingOn 08/15/2024, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 18Genvor Incorporated Appoints Judith Miller as Chief Business OfficerGenvor Incorporated announced Judith Miller has been asked to remain and transition from her successful Interim Chief Executive Officer position to serve as Chief Business Officer.お知らせ • Jan 17Genvor Incorporated Announces CEO ChangesGenvor Incorporated announced Chad Pawlak, Sr., global Agribusiness executive, has been appointed as Chief Executive Officer of Genvor, effective immediately. Judith Miller has been asked to remain and transition from her successful Interim Chief Executive Officer position to serve as Chief Business Officer. Chad Pawlak, Sr. brings over 30 years of experience with a proven track record of driving revenue growth and fostering strategic partnerships across agribusiness, regenerative agriculture, carbon marketing, food, and sustainability - particularly in soil and water conservation. He has a deep understanding of regenerative agriculture, biotechnology, crop cultivation, livestock management, dairy production, and consumer packaged goods (CPG). Most recently he was Chief Executive Officer of Locus Agricultural Solutions, an agricultural biological company, where he led the strategic growth plan through cross-functional collaboration, resulting in over 350,000 acres of enrollment in a nature-based carbon credit project utilizing a biological product as the practice change. Chad has previous experience as the U.S.-Canada Crop & Plant Protection Business Director Lead - Botanicals for MGK (a part of Valent USA & Sumitomo Chemical). In this role, he was responsible for the overall design of the strategic business plan of the $30 million Botanical & Organic Crop Protection segments in the U.S. & Canada. He holds an MBA from the Jack Welch Management Institute and BS & AOS in Marketing and Advertising/Public Relations from Johnson & Wales University.株主還元GNVRUS BiotechsUS 市場7D-37.8%2.4%1.1%1Yn/a34.6%28.7%株主還元を見る業界別リターン: GNVRがUS Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: GNVR US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is GNVR's price volatile compared to industry and market?GNVR volatilityGNVR Average Weekly Movementn/aBiotechs Industry Average Movement10.8%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: データは利用できません。時間の経過による変動: 過去 1 年間のGNVRのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a5Chad Pawlakwww.genvor.comGenvor Incorporatedは、農家が世界的な食糧安全保障を達成できるように設計された植物ベースの防衛技術を開発している。同社は以前はアリュール・ワールドワイド社として知られていたが、2022年6月にジェンボー・インコーポレイテッドに社名を変更した。本社はノースカロライナ州チャペルヒル。もっと見るGenvor Incorporated 基礎のまとめGenvor の収益と売上を時価総額と比較するとどうか。GNVR 基礎統計学時価総額US$16.59m収益（TTM）-US$1.29m売上高(TTM)n/a0.0xP/Sレシオ-12.8xPER（株価収益率GNVR は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計GNVR 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$1.29m収益-US$1.29m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.036グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-9.0%GNVR の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 01:48終値2026/05/19 00:00収益2026/03/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genvor Incorporated 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 23Genvor Incorporated Appoints Donald Kalkofen as Chief Financial OfficerGenvor Incorporated announced the appointment of Donald Kalkofen as Chief Financial Officer. In this role, Mr. Kalkofen will lead Genvor’s financial strategy as the company advances its dual-market commercialization plans across agriculture and human health and wellness. Mr. Kalkofen brings more than 20 years of Chief Financial Officer experience leading finance and operations across biotechnology, financial services, and technology, with a proven track record of guiding companies through initial public offerings and complex capital markets transactions. Most recently, he served as Chief Financial Officer of Alpha Cognition Inc., a publicly traded CNS-focused biotechnology company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s, where he led the preparations for the company’s successful NASDAQ listing and helped to establish new banking, audit committee, and investor relations functions. Prior to Alpha Cognition, Mr. Kalkofen served as Chief Financial Officer of Protagonist Therapeutics, a publicly traded clinical-stage biopharmaceutical company, where he helped guide the company’s strong growth and supported the company’s successful SOX 404(b) implementation. Earlier in his career, Mr. Kalkofen held Chief Financial Officer and senior finance leadership roles at Symantec Corporation and West Coast Bancorp, where he took the bank public on NASDAQ and led growth from $90 million to $1.5 billion in assets. Mr. Kalkofen is a Certified Public Accountant (inactive) and holds a Bachelor of Arts in Accounting from Washington State University.
お知らせ • Feb 11Genvor, Inc. Announces the Publication of Peer-Reviewed Research Validated Its Proprietary Agm182 Antifungal Peptide Technology in PhytofrontiersGenvor Inc. announced the publication of peer-reviewed research validating its proprietary AGM182 antifungal peptide technology in PhytoFrontiers™?, a journal of the American Phytopathological Society. The study, conducted in collaboration with the United States Department of Agriculture's Agricultural Research Service (USDA-ARS), demonstrates that transgenic corn expressing AGM182 achieves significant pre-harvest resistance to Aspergillus flavus and aflatoxin contamination. Aflatoxins are naturally occurring toxic and carcinogenic compounds produced by Aspergillus flavus that contain corn and other crops, posing significant risks to human and animal health. Economic losses fromungal diseases in corn are substantial, with total annual U.S. losses estimated between $3 billion and $5 billion. Aflatoxin contamination alone has potential annual market impacts ranging from approximately $52 million in lower-risk years to $1.68 billion in high-risk years. The peer-reviewed publication follows Genvor's November 2025 announcement that the USPTO issued U.S. Patent No. 12,458,684 for transgenic corn with antifungal peptide AGM182, co-assigned with the USDA. Together, the patent and publication provide both intellectual property protection and independent scientific validation of the technology's commercial potential. The research was conducted at the USDA-ARS Food and Feed Safety Research Unit at the Southern Regional Research Center in New Orleans, Louisiana, in collaboration with scientists from Tuskegee University and Genvor. The study builds on Genvor's over 7-year Cooperative Research and Development Agreement (CRADA) with the USDA-ARS, which focuses on developing corn varieties resistant to pre-harvest aflatoxin contamination.
お知らせ • Jan 28Genvor, Inc. Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, Effective February 2, 2026Genvor Inc. announced the appointment of Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, effective February 2, 2026. In this role, Dr. Stavrides will lead Genvor’s commercial strategy and execution, focusing on expanding strategic partnerships, licensing agreements, and collaboration opportunities with global agricultural companies. Dr. Stavrides brings more than 15 years of corporate experience in agrochemicals and biologicals, most recently serving as Global Product Management Lead, Biocontrols, at Syngenta. During his tenure, Dr. Stavrides and his team led the commercial evaluation of over 500 biological product concepts, managed over a dozen external collaborations, and oversaw over 50 product launches globally (microbials, extracts, pheromones), quadrupling revenues over a seven-year period. Previously, Dr. Stavrides held various global regulatory, strategy and marketing positions, in both agrochemicals and biocontrols. He has also served as company representative to the International Biocontrol Manufacturers Association (IBMA) for several years. Dr. Stavrides is a biochemist and also holds a Ph.D. in Genomics from Cambridge University (Human Genome Project) and an MBA from INSEAD.
お知らせ • Dec 12Genvor Incorporated Auditor Raises 'Going Concern' DoubtGenvor Incorporated filed its 10-K on Dec 10, 2025 for the period ending Sep 30, 2025. In this report its auditor, Novogradac & Company LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Dec 06Genvor Incorporated announced that it expects to receive $7 million in fundingGenvor Incorporated announced that it will receive $70,00,000 in funding on December 5, 2025. The company will issue common shares and warrants in the transaction. The minimum investment accepted from any outside investor is $10,000. The company will issue securities pursuant to exemption provided under Regulation D.
お知らせ • Aug 14Genvor Incorporated announced delayed 10-Q filingOn 08/13/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 23Genvor Incorporated Appoints Donald Kalkofen as Chief Financial OfficerGenvor Incorporated announced the appointment of Donald Kalkofen as Chief Financial Officer. In this role, Mr. Kalkofen will lead Genvor’s financial strategy as the company advances its dual-market commercialization plans across agriculture and human health and wellness. Mr. Kalkofen brings more than 20 years of Chief Financial Officer experience leading finance and operations across biotechnology, financial services, and technology, with a proven track record of guiding companies through initial public offerings and complex capital markets transactions. Most recently, he served as Chief Financial Officer of Alpha Cognition Inc., a publicly traded CNS-focused biotechnology company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s, where he led the preparations for the company’s successful NASDAQ listing and helped to establish new banking, audit committee, and investor relations functions. Prior to Alpha Cognition, Mr. Kalkofen served as Chief Financial Officer of Protagonist Therapeutics, a publicly traded clinical-stage biopharmaceutical company, where he helped guide the company’s strong growth and supported the company’s successful SOX 404(b) implementation. Earlier in his career, Mr. Kalkofen held Chief Financial Officer and senior finance leadership roles at Symantec Corporation and West Coast Bancorp, where he took the bank public on NASDAQ and led growth from $90 million to $1.5 billion in assets. Mr. Kalkofen is a Certified Public Accountant (inactive) and holds a Bachelor of Arts in Accounting from Washington State University.
お知らせ • Feb 11Genvor, Inc. Announces the Publication of Peer-Reviewed Research Validated Its Proprietary Agm182 Antifungal Peptide Technology in PhytofrontiersGenvor Inc. announced the publication of peer-reviewed research validating its proprietary AGM182 antifungal peptide technology in PhytoFrontiers™?, a journal of the American Phytopathological Society. The study, conducted in collaboration with the United States Department of Agriculture's Agricultural Research Service (USDA-ARS), demonstrates that transgenic corn expressing AGM182 achieves significant pre-harvest resistance to Aspergillus flavus and aflatoxin contamination. Aflatoxins are naturally occurring toxic and carcinogenic compounds produced by Aspergillus flavus that contain corn and other crops, posing significant risks to human and animal health. Economic losses fromungal diseases in corn are substantial, with total annual U.S. losses estimated between $3 billion and $5 billion. Aflatoxin contamination alone has potential annual market impacts ranging from approximately $52 million in lower-risk years to $1.68 billion in high-risk years. The peer-reviewed publication follows Genvor's November 2025 announcement that the USPTO issued U.S. Patent No. 12,458,684 for transgenic corn with antifungal peptide AGM182, co-assigned with the USDA. Together, the patent and publication provide both intellectual property protection and independent scientific validation of the technology's commercial potential. The research was conducted at the USDA-ARS Food and Feed Safety Research Unit at the Southern Regional Research Center in New Orleans, Louisiana, in collaboration with scientists from Tuskegee University and Genvor. The study builds on Genvor's over 7-year Cooperative Research and Development Agreement (CRADA) with the USDA-ARS, which focuses on developing corn varieties resistant to pre-harvest aflatoxin contamination.
お知らせ • Jan 28Genvor, Inc. Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, Effective February 2, 2026Genvor Inc. announced the appointment of Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, effective February 2, 2026. In this role, Dr. Stavrides will lead Genvor’s commercial strategy and execution, focusing on expanding strategic partnerships, licensing agreements, and collaboration opportunities with global agricultural companies. Dr. Stavrides brings more than 15 years of corporate experience in agrochemicals and biologicals, most recently serving as Global Product Management Lead, Biocontrols, at Syngenta. During his tenure, Dr. Stavrides and his team led the commercial evaluation of over 500 biological product concepts, managed over a dozen external collaborations, and oversaw over 50 product launches globally (microbials, extracts, pheromones), quadrupling revenues over a seven-year period. Previously, Dr. Stavrides held various global regulatory, strategy and marketing positions, in both agrochemicals and biocontrols. He has also served as company representative to the International Biocontrol Manufacturers Association (IBMA) for several years. Dr. Stavrides is a biochemist and also holds a Ph.D. in Genomics from Cambridge University (Human Genome Project) and an MBA from INSEAD.
お知らせ • Dec 12Genvor Incorporated Auditor Raises 'Going Concern' DoubtGenvor Incorporated filed its 10-K on Dec 10, 2025 for the period ending Sep 30, 2025. In this report its auditor, Novogradac & Company LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Dec 06Genvor Incorporated announced that it expects to receive $7 million in fundingGenvor Incorporated announced that it will receive $70,00,000 in funding on December 5, 2025. The company will issue common shares and warrants in the transaction. The minimum investment accepted from any outside investor is $10,000. The company will issue securities pursuant to exemption provided under Regulation D.
お知らせ • Aug 14Genvor Incorporated announced delayed 10-Q filingOn 08/13/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 13Genvor Incorporated announced delayed 10-Q filingOn 05/12/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 19Genvor Incorporated announced delayed 10-Q filingOn 02/18/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 01Genvor Incorporated announced delayed annual 10-K filingOn 01/31/2025, Genvor Incorporated announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Oct 23Genvor Incorporated Announces the Resignation of Judith S. Miller as Member of the Board of DirectorsOn August 7, 2024, Judith S. Miller resigned as a member of the Board of Directors of Genvor Incorporated (the Company).
お知らせ • Aug 16Genvor Incorporated announced delayed 10-Q filingOn 08/15/2024, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 18Genvor Incorporated Appoints Judith Miller as Chief Business OfficerGenvor Incorporated announced Judith Miller has been asked to remain and transition from her successful Interim Chief Executive Officer position to serve as Chief Business Officer.
お知らせ • Jan 17Genvor Incorporated Announces CEO ChangesGenvor Incorporated announced Chad Pawlak, Sr., global Agribusiness executive, has been appointed as Chief Executive Officer of Genvor, effective immediately. Judith Miller has been asked to remain and transition from her successful Interim Chief Executive Officer position to serve as Chief Business Officer. Chad Pawlak, Sr. brings over 30 years of experience with a proven track record of driving revenue growth and fostering strategic partnerships across agribusiness, regenerative agriculture, carbon marketing, food, and sustainability - particularly in soil and water conservation. He has a deep understanding of regenerative agriculture, biotechnology, crop cultivation, livestock management, dairy production, and consumer packaged goods (CPG). Most recently he was Chief Executive Officer of Locus Agricultural Solutions, an agricultural biological company, where he led the strategic growth plan through cross-functional collaboration, resulting in over 350,000 acres of enrollment in a nature-based carbon credit project utilizing a biological product as the practice change. Chad has previous experience as the U.S.-Canada Crop & Plant Protection Business Director Lead - Botanicals for MGK (a part of Valent USA & Sumitomo Chemical). In this role, he was responsible for the overall design of the strategic business plan of the $30 million Botanical & Organic Crop Protection segments in the U.S. & Canada. He holds an MBA from the Jack Welch Management Institute and BS & AOS in Marketing and Advertising/Public Relations from Johnson & Wales University.
